ASCO 2018

Aktuelles in 100 Sekunden - Die Idee

Aktuelles in 100 Sekunden - Fazit

Biosimilar ABP 980

Biosimilars ASCO 2018

MBC HR+/HER2-: MONALEESA-3, PALOMA-2, Monarch 3

MBC HER2+: Trastuzumab deruxtecan in subjects previously treated with T-DM1

MBC HR+/HER2-: Sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate)

EBC BRCA+: Prophylactic irradiation to the contralateral breast for BRCA mutation carriers

EBC BRCA+: Neoadjuvant talazoparib for operable breast cancer patients

TNBC: GeparNuevo - The addition of durvalumab to a taxane-anthracycline containing neoadjuvant chemotherapy

ASCO 2018 - Mammakarzinom

ASCO 2018 - Mammakarzinom

Persistence of circulating tumor cells in high risk EBC five years after adjuvant chemotherapy

EBC HER2+: PERSEPHONE (6 vs. 12 months trastuzumab) & PERELISA De-escalated neodajuvant treatment with trastuzumab-pertuzumab-letrozole

EBC HR+/HER2-: TAILORx: Chemoendocrine therapy vs. endocrine therapy alone - ab dem 8. Juni 2018

Irradiation therapy: EORTC Trial 22922/10925 and Pembrolizumab plus radiotherapy in mTNBC

PI3K & AKT Pathway: SANDPIPER - Taselisib, PAKT - Capivasertib & LOTUS - Ipatasertib

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial

CDK 4/6 Update

Melanom Highlights

Hematologic Malignancies - Plasma Cell Dyscrasia

A.R.R.O.W.

OPTIMISMM

Arthralgieschmerz, Polyneuropathie, Rash

Metastasiertes Urothelkarzinom

mRCC: CARMENA - Cytoreductive nephrectomy aus der Sicht eines Urologen

Nierenzellkarzinom

Blasenkarzinom - Übersicht und PD-L1 Testung

Immunantwort

Immunonkologie Prostatakarzinom

mRCC: CARMENA - Cytoreductive nephrectomy aus der Sicht eines Onkologen

CML & NSCLC

ASCO Voices

Neue Guideline Geriatrisches Assessment

Kopf-Hals-Tumoren

Weichgewebssarkome

Outtakes